

ENDRA Life Sciences Inc.

Reports Q2 inline. New CEO and game plan. We believe FDA approval and EU/US product launch over the next year to drive stock. Lowering P/T to \$10.

Q2 about inline: ENDRA recently (on August 22) reported its Q2 2024 (ending June) results. Net loss was \$2.2 million or EPS of \$(4.09) compared with our estimates of \$(3.25). There was no Q2 guidance or consensus estimates. ENDRA is a late stage medical device development/early stage commercialization company so it generates no revenues.

Operating expense: Operating expenses were \$2.2 million, vs \$2.8 million in Q1 on lower R&D and G&A costs.

No 2024 guidance: Management did not provide 2024 financial guidance.

Adjusting 2024 estimates: We are adjusting our 2024 estimates for revenues to \$0 from \$0.1 million, and for EPS to \$(11.08) from \$(11.62).

New CEO: In August, ENDRA appointed Alexander Tokman as acting CEO to replace Francois Michelon. Mr. Tokman is a growth-driven executive with 24+ years of experience in the development and commercialization of new technology products and services for Medical Device, Biotech, Consumer Electronics, AI and AgTech markets.

New focus on clinical data: ENDRA is now focused on getting more key clinical data to support the FDA application and commercialization.

New CFO: The company also added Ziad Rouag as Head of Regulatory and Clinical Affairs and Richard Jacroux as CFO.

Focused on TAEUS development: ENDRA has one main medical device candidate, the Thermo Acoustic Enhanced UltraSound (TAEUS) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT and MRI, but at a fraction of the cost and at the point-of-care.

FDA decision delayed to 2025: On August 14, 2023, ENDRA filed its De Novo application with the FDA. The FDA's target approval date is 150 days (~5 months or about January 15, 2024). On May 20, ENDRA announced that it has met with the FDA. Based on the feedback received, ENDRA will update its pivotal clinical study protocol and statistical plan for submission to the FDA as a next step prior to initiating the study. This will require additional data and a resubmitted application in 1H 2025.

EU launched: In March 2020, ENDRA received CE Mark approval, and is now starting initial commercialization activity in Europe.

Large market opportunity: The company is launching its first TAEUS application to measure fat in the liver, which is used for early detection and monitoring of Steatotic Liver Disease (SLD) (aka Non-Alcoholic Fatty Liver Disease (NAFLD)). In 2011, over 1.4 billion people were affected by SLD/NAFLD/NASH around the world. Despite the increased incidence of SLD/NAFLD, there are no low-cost, accurate, and safe methods for measuring fat in the liver. TAEUS technology should enable to diagnose SLD earlier and monitor patients with related liver diseases more accurately and cost-effectively than is possible with existing technology.

Balance sheet: In Q2, ENDRA has \$6 million in cash and no debt. In Q2, the company raised ~\$8 million selling stock. We believe it has enough cash into 2025.

Stock split: The company effected a 1-for-50 reverse stock split in August 2024. **Current valuation attractive**: Maintaining our BUY rating, but lowering our 12month price target to \$10 from \$400. This is based on a NPV analysis, representing significant upside from the current share price. We believe this valuation appropriately balances out the company's high risks with the company's high growth prospects and large upside opportunities.

Company Description

Based in Ann Arbor, MI, ENDRA Life Sciences is a medical device company developing enhanced ultrasound technologies (TAEUS) for medical imaging.

United States Healthcare

September 10, 2024

Edward Woo, CFA (561) 327-9435 ewoo@ascendiant.com

Stock Data

Exchange:	NasdaqCM
52-week Range:	\$0.24 – 139.50
Shares Outstanding (million):	1.5
Market cap (\$million):	~\$1
EV (\$million):	\$(6)
Debt (\$million):	\$0
Cash (\$million):	\$6
Avg. Daily Trading Vol. (\$million):	\$1
Float (million shares):	1.5
Short Interest (million shares):	0.2
Dividend, annual (yield):	\$0 (NA%)

Revenues (US\$ million)

	<u>2024E</u> (Cur.)	<u>2024E</u> (Old)	<u>2025E</u> (Cur.)	<u>2025E</u> (Old)
Q1 Mar	0.0A		0.0E	0.1E
Q2 Jun	0.0A	0.0E	0.0E	0.1E
Q3 Sep	0.0E		0.0E	0.1E
Q4 Dec	<u>0.0E</u>	0.1E	0.3E	<u>0.5E</u>
Total	0.0E	0.1E	0.3E	0.8E
EV/Revs	N/A		N/A	

Earnings per Share (pro forma)

	<u>2024E</u> <u>(Cur.)</u>	<u>2024E</u> (Old)	<u>2025E</u> <u>(Cur.)</u>	<u>2025E</u> (Old)
Q1 Mar	(12.84)A		(2.25)E	(2.11)E
Q2 Jun	(4.09)A	(3.25)E	(2.25)E	(2.11)E
Q3 Sep	(1.78)E	(2.08)E	(2.25)E	(2.11)E
Q4 Dec	<u>(1.78)E</u>	<u>(2.05)E</u>	<u>(2.16)E</u>	<u>(2.05)</u> E
Total	(11.08)E	(11.62)E	(8.91)E	(8.38)E
P/E	N/A		N/A	

*Reflects a 1:50 reverse stock split in August 2024.

Important Disclosures

Ascendiant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 13.

Rating: BUY

COMPANY

UPDATE

Ticker:	NDRA							
Price:	\$0.27							
Target:	\$10							
(from \$400)								



Exhibit 1: Q2 2024 Results and Recent Highlights (as of August 22, 2024)

August 22, 2024 1:14 PM

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

Conference call begins at 4:30 p.m. Eastern time today

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS[®]), reports financial results for the three and six months ended June 30, 2024, as filed in a Form 10-Q on August 14, 2024, and provides the following business update:

New executive team

 Subsequent to quarter-end, ENDRA announced leadership changes. Board member Alexander Tokman was appointed as acting CEO, bringing 24+ years of global commercial leadership experience. Additionally, two industry veterans joined in key roles including regulatory and clinical affairs, and finance. Richard Jacroux, new Chief Financial Officer, has over 20 years of experience in financial management and accounting and has held the role of CFO at several technology companies. Ziad Rouag, Head of Regulatory and Clinical Affairs, brings to ENDRA more than two decades of experience in the medical device industry as a leader of clinical operations and regulatory affairs for emerging startups and high-growth businesses.

Focus on clinical and regulatory activities

- Advanced the U.S. regulatory process. ENDRA met with the U.S. Food and Drug Administration (FDA) at their headquarters in Maryland to demonstrate the TAEUS technology and review the clinical and statistical plans. The meeting minutes confirmed alignment on the topics discussed and the steps required for a successful regulatory outcome. To drive the process forward, ENDRA has hired Mr. Rouag, an experienced regulatory and clinical leader.
- Started new pilot clinical trials. New pilot trials were initiated at two clinical sites in North America and one is expected to commence in Europe to generate data that support TAEUS' value to clinical users. ENDRA will use the data from these sites to demonstrate the TAEUS system's performance to the FDA before initiating the De Novo pivotal study.
- Expanded the intellectual property portfolio, now with 81 issued patents globally. During the second quarter of 2024, ENDRA was issued five additional patents, including three in Europe and two in China, ENDRA's broad intellectual property portfolio provides protection for the TAEUS system with its novel thermoacoustic technology and the opportunity to explore licensing opportunities for indications beyond its core focus.

Raised capital and significantly reduced operating expenses

- Raised \$8.0 million in a public offering. The company raised approximately \$8.0 million in gross proceeds from the sale of common stock and warrants in a public offering.
- Significantly reduced operating expenses. As part of focusing resources on clinical and regulatory activities, ENDRA restructured
 operations, reducing annualized expenses by \$3.1 million compared with the prior-year second quarter.

"In the near-term, the company is prioritizing securing the clinical data to support a new De Novo regulatory filing with the FDA above all other goals," said Alexander Tokman, acting Chief Executive Officer. "In parallel, we are revisiting our go-to-market strategy for TAEUS to ensure we are prioritizing the most promising vertical markets while formalizing our longer-term business strategy and crystalizing our vision for ENDRA. All of this is being done with careful attention to operating expenses, which we recently reduced by 26% on an annualized basis without impacting any of our primary deliverables."



Exhibit 2: ENDRA Investment Highlights

ENDRA Life Sciences

ENHANCE ULTRASOUND TO SEE HUMAN TISSUE IN WAYS SIMILAR TO CT-MRI... BUT AT 50X LOWER COST²

Investment Highlights

\$12.5 BILLION¹ INITIAL MARKET

- Measure liver fat for assessment of Steatotic Liver Disease (formerly known as NAFLD-NASH or "fatty liver disease")
- Affects 2 billion people globally²
- Diagnostic gap with no current practical tools
- First therapeutic (Rezdiffra™) for fatty liver disease approved March 2024³, representing additional driver for identification of liver fat

PROPRIETARY, SCALABLE PLATFORM

- ✓ Similar to MRI but 1/40th the cost⁴ and at point of patient care
- Platform enables multiple potential clinical applications & revenue streams
- 75 patents issued (zero in-licensing)
- ✓ CE mark received in Europe
- De Novo pre-submission meeting scheduled with U.S. FDA


CAPITAL-EFFICIENT MODEL

- Lean and deeply experienced management team
- World-class technical, clinical and commercial partners



Exhibit 3: TAEUS Planned Milestones

Key Milestones Achieved & Anticipated Future Catalysts



Source: Company reports.



Exhibit 4: ENDRA Partners

Value-Added Partner Ecosystem

Leverage partnerships to amplify ENDRA's technical, clinical and commercial activities

TECHNOLOGY

ROBUST CLINICAL EVIDENCE

- Peer-leading IP portfolio
- Novel cloud-based data mgt.
- Artificial Intelligence tools
- Collaborations to co-develop & potentially integrate TAEUS applications



Source: Company reports.

- Clinical data supporting regulatory submissions & commercialization
- Studies comparing TAEUS to MRI-PDFF in target markets: U.S., EU, Asia
- Pharma pilot of TAEUS for drug trial recruitment efficiencies



COMMERCIAL ADOPTION

- Target clinicians in Germany, France, UK & USA with small ENDRA sales team & partners
- Leverage clinical publications & in-country reference sites
- Demonstrate TAEUS at key global clinical conferences
- Online education & marketing
- Distributors in secondary mkts.



(Vietnam distributor)



Exhibit 5: ENDRA's TAEUS Liver Fat Opportunity (Steatotic Liver Disease (SLD) aka NASH - NAFLD)

The Problem: Steatotic Liver Disease (SLD)

CONVERGENCE OF PIVOTAL FACTORS CREATE OPPORTUNITY FOR ENDRA TO ADDRESS LARGE UNMET DIAGNOSTIC NEED

BROAD & PERSISTENT DRIVERS	HEAVY PUBLIC HEALTH BURDEN	DIAGNOSTIC & TREATMENT GAPS
Lifestyle / Obesity Diabetes Genetics Polycystic Ovarian Syndrome HIV Certain drugs [E.g., chemotherapy]	 2+ billion¹ people globally affected by excess fat in the liver. > 6% liver fat is of clinical concern Often asymptomatic, can progress to inflammation, cirrhosis, cancer Leading cause of liver transplants in U.S. by 2030² Cardiovascular disease^{3,4} 1.6x Chronic kidney disease^{3,4} 1.2x \$100B direct U.S. medical costs⁵ 	 Diagnostics gap MRI: \$2.5M, 5 tons, complicated to use, slow, concentrated in cities Liver biopsy: Invasive, painful, requires surgical training Blood tests: low precision Historically no effective treatments Weight loss low compliance New drugs entering market

The Opportunity: Improved Diagnostics To Drive Adoption of New Treatments

FIRST APPROVED STEATOTIC LIVER DISEASE (SLD) THERAPIES EXPECTED IN 2023^{1,2} INTENSIFYING NEED TO IDENTIFY & MONITOR PATIENTS



The Opportunity: Assess Liver Fat of 2⁺ Billion SLD Patients

INTRODUCE A TOOL THAT BALANCES DIAGNOSTIC VALUE + ACCESSIBILITY






Exhibit 6: TAEUS

Thermo Acoustic Enhanced Ultrasound: TAEUS®

Encouraging early clinical data published in September 2023

TAEUS® SYSTEM

- System consists of a console, probe and display
- Results do not require a radiological interpretation
- Obese and fibrotic¹ patients are not excluded
- Total procedure takes ~10 minutes

CLINICAL VALIDATION & REGULATORY STATUS

- ✓ CE mark received in Europe
- ✓ TAEUS[®] clinical studies published by EASL²

TAEUS® Correlation to MRI-PDFF: r = 0.87

At 6% liver fat threshold: Sensitivity = 95% and Specificity = 77% Negative Predictive Value (NPV): 95%

✓ De Novo pre-submission meeting scheduled with U.S. FDA



Commercializing TAEUS Liver: 3 Core Elements







Exhibit 7: TAEUS Potential Market Opportunities

Total Addressable Markets for TAEUS®: Liver & Other Applications




ENDRA's TAEUS® Platform & Business Model

First TAEUS® application assesses liver fat, with licensing opportunities in other indications

Multiple Tissue Characterization Capabilities*	Translatable Into a Range of Clinical Applications*	Monetized Through Diverse Potential Revenue Streams
	Current Focus	Products TAEUS® system at point-of-
Tissue Composition	 Measure liver fat for Steatotic Liver Disease (formerly NAFLD-NASH) 	patient-care
		Software Diverse clinical apps added to the TAEUS® product
	Future Potential Applications	
Tissue Temperature Variation*	 Guide energy-based procedures for cancer, pain, cardiology, aesthetics 	Services Pay-per-scan, rentals, maintenance agreements
		Disposables E.g., Per-procedure applicator pads
Tissue Fluid Flows*	 Visualize blocked vessels and micro-vascular fluid flows (e.g., perfusion) 	Licensing Build TAEUS [®] into OEM ultrasounds, surgical robotics, etc.



Exhibit 8: ENDRA Life Sciences Stock Price (5-years)





FINANCIAL MODEL

Sear Vax Find O1A Q2A Q3A Q1A Q2A Q3A Q	ncome Statement (\$ mils)	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	202
Control Cont	iscal Year End: December 31															-					FY-
Control Cont																					
Gross Profit 0.0	Total Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0
Gross Profit 0.0	Cost of Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0
Research and development 1.2 1.8 1.8 1.7 6.6 1.4 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>																					
Sales and marketing _ income lenger 0.3 0.3 0.4 0.3 1.4 1.2 1.3 1.4 <td>Gloss Floh</td> <td></td> <td>0.0</td> <td>0.0</td> <td></td> <td>0.0</td> <td></td> <td>0.0</td> <td>0.0</td> <td>0.0</td> <td>0.1</td> <td></td>	Gloss Floh		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.1	
General and administrative Total operating expenses 1.3 1.4 1.2 1.3 5.2 1.4 1.3 1.3 0.7 4.7 1.5 1.4 1	Research and development	1.2	1.8	1.8		6.6	1.4	1.4	1.6	0.6	5.0	1.0	0.7	1.0	1.0		1.4	1.4	1.4		5
Estimuting and other Total operating express 2.9 3.6 3.4 3.3 13.2 2.9 3.0 3.1 1.5 0.0 2.8 2.2 2.6 2.0 1.0.2 3.3 3.3 3.3 3.3 Opprating income (loss) (2.9) (3.6) (3.4) (3.3) (1.2) (2.9) (3.0) (3.1) (1.5) (10.5) (2.8) (2.2) (2.6) (1.2) (3.3) (3.	Sales and marketing	0.3	0.3			1.4	0.2		0.2	0.1	0.8	-	0.2	0.2	0.2	0.8	0.5	0.5	0.5	0.5	2
Total operating expenses 2.9 3.6 3.4 3.3 132 2.9 3.0 3.1 1.5 10.5 2.8 2.2 2.6 2.6 10.2 3.3 <	General and administrative	1.3	1.4	1.2	1.3	5.2	1.4	1.3	1.3	0.7	4.7	1.5	1.4	1.4	1.4	5.7	1.4	1.4	1.4	1.4	1
Construction Case of the constru	Restructuring and other					0.0					0.0					0.0					(
Line Line <thline< th=""> Line Line <thl< td=""><td>Total operating expenses</td><td>2.9</td><td>3.6</td><td>3.4</td><td>3.3</td><td>13.2</td><td>2.9</td><td>3.0</td><td>3.1</td><td>1.5</td><td>10.5</td><td>2.8</td><td>2.2</td><td>2.6</td><td>2.6</td><td>10.2</td><td>3.3</td><td>3.3</td><td>3.3</td><td>3.3</td><td>13</td></thl<></thline<>	Total operating expenses	2.9	3.6	3.4	3.3	13.2	2.9	3.0	3.1	1.5	10.5	2.8	2.2	2.6	2.6	10.2	3.3	3.3	3.3	3.3	13
Other income (aspense) (0.0)	Operating income (loss)	(2.9)	(3.6)	(3.4)	(3.3)	(13.2)	(2.9)	(3.0)	(3.1)	(1.5)	(10.5)	(2.8)	(2.2)	(2.6)	(2.6)	(10.2)	(3.3)	(3.3)	(3.3)	(3.2)	(13
Other income (aspense) (0.0)	latarat income (avarage)					0.0	(0,0)			0.0	0.0			0.0	0.0	0.0		0.0	0.0		
Income before income taxes (2.9) (3.6) (3.4) (3.3) (1.32) (2.9) (2.6) (3.1) (1.5) (1.0.1) (2.8) (2.2) (2.6) (2.6) (3.1) (1.5) (1.0.1) (2.8) (2.2) (2.6) (2.6) (3.1) (1.5) (1.0.1) (2.8) (2.2) (2.6) (2.6) (3.1) (1.5) (1.0.1) (2.8) (2.2) (2.6) (2.6) (3.1) (1.5) (1.0.1) (2.8) (2.2) (2.6) (2.6) (2.6) (2.1)		(0.0)	(0.0)	(0.0)	0.0		(0.0)	0.4	0.0			0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	
Income Laws 0.0 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>(0.0)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>(0.0)</td><td>(0.0)</td><td></td><td>(0.0)</td><td>(0.0)</td><td>(0.0)</td><td>(0.0)</td><td></td></th<>							(0.0)							(0.0)	(0.0)		(0.0)	(0.0)	(0.0)	(0.0)	
Net income (loss) (2.9) (3.6) (3.4) (3.3) (13.2) (2.9) (2.6) (3.1) (1.5) (10.1) (2.8) (2.2) (2.6) (10.2) (3.3) (3.1) (1.5)		(2.9)	(3.6)	(3.4)	(3.3)		(2.9)	(2.6)	(3.1)	(1.5)	· · · ·	(2.8)	(2.2)								
Non-model information Carbon			(0.0)				(0.0)					(2.2)									
Net income (pro forma) (2.9) (3.6) (3.4) (3.3) (13.2) (2.9) (2.6) (3.1) (1.5	Net income (loss)	(2.9)	(3.6)	(3.4)	(3.3)	(13.2)	(2.9)	(2.6)	(3.1)	(1.5)	(10.1)	(2.8)	(2.2)	(2.6)	(2.6)	(10.2)	(3.3)	(3.3)	(3.3)	(3.2)	(1:
EBITDA Shares, Daixe 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.5 1.5	Nonrecurring/noncash adjustme	<u>nts</u>				<u>0.0</u>					<u>0.0</u>										
Shares, Basic Shares, Diluted 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.5 1.5 1.5 0.9 1.5	Net income (pro forma)	(2.9)	(3.6)	(3.4)	(3.3)	(13.2)	(2.9)	(2.6)	(3.1)	(1.5)	(10.1)	(2.8)	(2.2)	(2.6)	(2.6)	(10.2)	(3.3)	(3.3)	(3.3)	(3.2)	(1
Shares, Diluted 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.5 1.5	EBITDA																				
Shares, Diluted 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.5 1.5	Shares, Basic	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.2	0.5	1.5	1.5	0.9	1.5	1.5	1.5	1.5	
EPS Diluted (Pro forma) (\$66.39) (\$58.25) (\$54.46) (\$27.91) (\$46.43) (\$21.32) (\$20.18) (\$8.49) (\$79.04) (\$1.78) (\$1.78) (\$1.78) (\$1.78) (\$1.78) (\$1.78) (\$1.78) (\$2.25) <th< td=""><td></td><td>0.0</td><td>0.1</td><td>0.1</td><td>0.1</td><td></td><td>0.1</td><td>0.1</td><td></td><td></td><td>0.1</td><td>0.2</td><td></td><td></td><td>1.5</td><td>0.9</td><td></td><td></td><td></td><td></td><td></td></th<>		0.0	0.1	0.1	0.1		0.1	0.1			0.1	0.2			1.5	0.9					
EPS Diluted (Pro forma) (\$66.39) (\$58.25) (\$54.46) (\$27.91) (\$46.43) (\$21.32) (\$20.18) (\$8.49) (\$79.04) (\$1.78) (\$1.78) (\$1.78) (\$1.78) (\$1.78) (\$1.78) (\$1.78) (\$2.25) <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>																					
Margins Gross margin Research and development Sales and marketing General and administrative Operating margin NM	EPS Basic (Pro forma)	(\$66.39)	(\$58.25)	(\$54.46)	(\$51.89)	(\$227.91)	(\$46.43)	(\$21.32)	(\$20.18)	(\$8.49)	(\$79.04)	(\$12.84)	(\$4.09)	(\$1.78)	(\$1.78)	(\$11.08)	(\$2.25)	(\$2.25)	(\$2.25)	(\$2.16)	(\$8
Gross margin Research and development Sales and marketing General and administrative Operating margin NM NM </td <td>EPS Diluted (Pro forma)</td> <td>(\$66.39)</td> <td>(\$58.25)</td> <td>(\$54.46)</td> <td>(\$51.89)</td> <td>(\$227.91)</td> <td>(\$46.43)</td> <td>(\$21.32)</td> <td>(\$20.18)</td> <td>(\$8.49)</td> <td>(\$79.04)</td> <td>(\$12.84)</td> <td>(\$4.09)</td> <td>(\$1.78)</td> <td>(\$1.78)</td> <td>(\$11.08)</td> <td>(\$2.25)</td> <td>(\$2.25)</td> <td>(\$2.25)</td> <td>(\$2.16)</td> <td>(\$8</td>	EPS Diluted (Pro forma)	(\$66.39)	(\$58.25)	(\$54.46)	(\$51.89)	(\$227.91)	(\$46.43)	(\$21.32)	(\$20.18)	(\$8.49)	(\$79.04)	(\$12.84)	(\$4.09)	(\$1.78)	(\$1.78)	(\$11.08)	(\$2.25)	(\$2.25)	(\$2.25)	(\$2.16)	(\$8
Gross margin Research and development Sales and marketing General and administrative Operating margin NM NM </td <td></td> <td>-</td>																					-
Research and development Sales and marketing General and administrative Operating margin NM <	•													500/	500/	#DIV//01	500/	500/	500/	500/	5
Sales and marketing General and administrative Operating margin NM																					
General and administrative Operating margin NM																					
Operating margin NM	•																				
Tax rate, GAAP 0%																					
Net margin NM	1 0 0																				-523
W1 % change Total Revenue Gross margin 6% 56% 17% 20% 15% -24% -11% -65% -24% -25% -49% -39% 73% -25% 44% -11% -25% -43% -18% 35% -24% -25% -43% -31% -35% -26% -11% -25% -43% -31% -35% -26% -11% -25% -49% -39% 73% -25% 44% -36% -26% -43% 31% -34% -18% 35% -2% 40% 0% 10% 20% 15% 5% -3% 7% -44% -9% 10% 0% 10% 20% 15% 5% -3% 7% -44% -9% 10% 0%																					
Total Revenue Gross margin 6% 56% 17% 20% 15% -24% -11% -65% -24% -25% -49% -39% 73% -25% 44% -11% -21% -11% -21% -11% -21% -24% -24% -24% -24% -24% -24% -24% -24% -24% -24% -25% -49% 73% -25% 44% -24% -24% -24% -24% -24% -24% -24% -24% -25% -49% 73% -25% 44% -36% -24% -26% -49% -35% -26% -49% -36% -26% -37% 75% -36% -26% -49% -36%	Net margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	-1270%	-523
Gross margin #DIV/0!	Y/Y % change																				
Research and development 6% 6% 56% 17% 20% 15% -24% -11% -65% -24% -25% -49% -39% 73% -25% 34% 95% 40% 40% Sales and marketing 111% 33% 53% -14% 33% -28% -42% -55% -43% 31% -34% -18% 35% -2% 110% 207% 150% 150% 1 General and administrative 2% 15% -3% 7% -45% -9% 10% 0% 12% 20% 7% 40% 0% <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>																					
Sales and marketing 111% 33% 53% -14% 33% -28% -42% -55% -43% 31% -34% -18% 35% -2% 110% 207% 150% 150% 1 General and administrative 2% 15% -3% 5% -4% -9% 10% 0% 12% 20% 7% 4% 0%	Gross margin																				
General and administrative 2% 15% -3% 4% 5% 5% -3% 7% -45% -9% 10% 0% 12% 92% 20% -7% 4% 0% 0% Operating income (loss) 11% 12% 29% 8% 14% 3% -16% -8% -56% -20% -5% -26% -17% 78% 19% 48% 27% 22% Net income (loss) 20% 12% 29% 6% 16% 3% -29% -10% -56% -24% -6% -13% -16% 78% 1% 19% 48% 27% 22%	Research and development					20%			-11%			-25%	-49%	-39%			34%	95%	40%		
Operating income (loss) 11% 12% 29% 8% 14% 3% -16% -8% -56% -20% -57% -26% -17% 78% -3% 19% 48% 27% 22% Net income (loss) 20% 12% 29% 6% 16% 3% -29% -10% -56% -24% -6% -13% -16% 78% 1% 19% 48% 27% 22%	Sales and marketing	111%	33%	53%	-14%	33%	-47%	-28%	-42%	-55%	-43%	31%	-34%	-18%	35%	-2%	110%	207%	150%	150%	1
Net income (loss) 20% 12% 29% 6% 16% 3% -29% -10% -56% -24% -6% -13% -16% 78% 1% 19% 48% 27% 22%	General and administrative	2%	15%	-3%	4%	5%	5%	-3%	7%	-45%	-9%	10%	0%	12%	92%	20%	-7%	4%	0%	0%	
	Operating income (loss)	11%	12%	29%	8%	14%	3%	-16%	-8%	-56%	-20%	-5%	-26%	-17%	78%	-3%	19%	48%	27%	22%	1
	Net income (loss)	20%	12%	29%	6%	16%	3%	-29%	-10%	-56%	-24%	-6%	-13%	-16%	78%	1%	19%	48%	27%	22%	
		5%	-24%	-14%	-29%	-18%	-30%	-63%	-63%	-84%	-65%	-72%	-81%	-91%	-79%	-86%	-82%	-45%	26%	21%	-2

Source: Company reports and Ascendiant Capital Markets estimates.

Reflects a 1:50 reverse stock split in August 2024



ENDRA Life Sciences Inc.

Balance Sheet (\$ mils)	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
				-										-		
Assets																
Cash and cash equivalents	7.1	11.3	8.0	4.9	2.4	4.8	3.3	2.8	1.1	6.4	4.3	1.6	(1.5)	(4.7)	(7.8)	(10.4)
Short term investments											0.0	0.0	0.0	0.0	0.0	0.0
Accounts receivable, net											0.0	0.0	0.0	0.0	0.0	0.3
Inventory	1.9	2.4	2.6	2.6	2.7	2.8	2.8				0.0	0.0	0.0	0.0	0.0	0.0
Deferred income taxes											0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses and other	1.1	0.8	0.9	1.0	0.4	0.5	0.3	0.2	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.1
Total current assets	10.1	14.5	11.6	8.5	5.5	8.1	6.4	3.0	1.3	6.7	4.3	1.6	(1.5)	(4.7)	(7.8)	(10.0)
Property and equipment, net	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2
Intangibles, net											0.0	0.0	0.0	0.0	0.0	0.0
Inventory								2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
Deferred income tax											0.0	0.0	0.0	0.0	0.0	0.0
Other	0.6	0.6	<u>0.5</u>	<u>0.5</u>	<u>0.9</u>	<u>1.0</u>	<u>1.0</u>	<u>1.0</u>	<u>1.0</u>	0.9	<u>0.9</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>
Total assets	10.9	15.3	12.3	9.3	6.7	9.2	7.6	6.8	5.1	10.4	8.0	4.4	1.3	(1.8)	(4.9)	(7.0)
Liabilities and stockholders' equity																
Accounts payable	1.2	1.4	1.6	1.5	1.6	1.8	2.0	0.7	1.0	1.2	1.2	0.0	0.0	0.0	0.0	0.8
Accrued expenses											0.0	0.0	0.0	0.0	0.0	0.1
Deferred income tax											0.0	0.0	0.0	0.0	0.0	0.0
Other	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Short term debt				<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>			<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>
Total current liabilities	1.4	1.5	1.7	1.7	1.8	2.0	2.2	0.9	1.2	1.4	1.4	0.2	0.2	0.2	0.2	1.1
Deferred income taxes											0.0	0.0	0.0	0.0	0.0	0.0
Warrant liabilities											0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.5	0.4	0.4	0.4	0.3	0.3	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Long term debt	0.0	0.0	0.0								<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>
Total other liabilities	0.5	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Preferred stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1
Additional paid-in capital	80.6	88.5	88.8	89.1	89.3	94.3	95.7	97.6	98.4		105.9	105.9	105.9	105.9	105.9	105.9
Retained earnings	(71.5)	(75.1)	(78.6)	(81.9)	(84.8)	(87.4)	(90.5)	(91.9)	(94.7)	(96.9)	(99.5)	(102.1)	(105.4)	(108.7)	(112.0)	(115.2)
Accumulated other comprehensive in	· · · ·	(75.1)	(10.0)	(01.9)	(04.0)	(07.4)	(90.3)	(91.9)	(94.7)	(90.9)	(99.5)	0.0	0.0	0.0	0.0	(115.2)
Other	1	0.0	0.0	0.0	0.0						0.0	0.0	0.0	0.0	0.0	0.0
Total stockholders' equity	<u>0.0</u> 9.1	<u>0.0</u> 13.3	<u>0.0</u> 10.2	<u>0.0</u> 7.2	<u>0.0</u> 4.5	6.9	5.2	5.7	3.7	9.0	<u>0.0</u> 6.6	<u>0.0</u> 4.2	<u>0.0</u> 1.1	(2.1)	(5.2)	(8.2)
i otal stockholders equity	5.1	13.3	10.2	1.2	4.5	0.9	5.2	5.7	3.7	5.0	0.0	4.2		(2.1)	(3.2)	(0.2)
Total stockholders' equity and liabil	10.9	15.3	12.3	9.3	6.7	9.2	7.6	6.8	5.1	10.4	8.0	4.4	1.3	(1.8)	(4.9)	(7.0)

Balance Sheet Drivers

	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Prepaid as % of total rev												50%	50%	50%	50%	50%
Accounts payable as % of total rev												300%	300%	300%	300%	300%
Inventories as % of cost of rev												20%	20%	20%	20%	20%
Accrued expenses as % of total rev												50%	50%	50%	50%	50%
Activity Ratios																
A/R Days Sales Outstanding												100		100	100	100
Inventory Turnover														#DIV/0!		20.0×
A/P Days Payable												#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	540
Book & Cash Value (per share)																
Book Value per Share (diluted)	######	######	######	######	\$70.98	\$57.79	\$33.81	\$32.90	\$17.11	\$16.48	\$4.51	\$2.85	\$0.72	-\$1.40	-\$3.52	-\$5.55
Cash per Share (diluted)	######	######	######	\$77.12	\$37.16	\$40.19	\$21.70	\$16.48	\$5.25	\$11.73	\$2.93	\$1.10	-\$1.04	-\$3.17	-\$5.33	-\$7.06
Net cash per Share (diluted)	######	######	######	\$76.67	\$36.71	\$39.95	\$21.51	\$16.31	\$5.25	\$11.73	\$2.93	\$1.10	-\$1.04	-\$3.17	-\$5.33	-\$7.06
Source: Company reports and Ascendia	ant Canita	I Market	s estima	tes												

Source: Company reports and Ascendiant Capital Markets estimates



ash Flow Statement (\$ mils)	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025
iscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Cash flow from operating activit	ies																			
Net income	(2.9)	(3.6)	(3.4)	(3.3)	(13.2)	(2.9)	(2.6)	(3.1)	(1.5)	(10.1)	(2.8)	(2.2)	(2.6)	(2.6)	(10.2)	(3.3)	(3.3)	(3.3)	(3.2)	(13.
Depreciation	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.
Amortization	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	ő
Debt related amortization expension		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0					0
Stock comp	0.3	0.3	0.3	0.3	1.2	0.2	0.3	0.3	0.3	1.0	0.3	0.2	0.2	0.2	0.9	0.2	0.2	0.2	0.2	0
Deferred income taxes	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in fair value of warrant li	ahility				0.0					0.0					0.0					0
Writedowns and impairments	ability			0.0	0.0				0.2	0.2	0.2	(0.1)			0.0					
Other gains/losses				0.0	0.0				0.2	0.0	0.2	(0.1)			0.0					
Other					0.0					0.0					0.0					
Changes in operating assets and li	abilities [.]				0.0					0.0					0.0					
Accounts receivable	abiiitioo.				0.0					0.0			0.0	0.0	0.0	0.0	0.0	0.0	(0.3)	(
Inventory	(0.6)	(0.4)	(0.3)	(0.0)	(1.4)	(0,1)	(0.0)	0.0	(0.0)	(0.1)	(0.2)	0.1	0.0	0.0	(0.1)	0.0	0.0	0.0	(0.0)	i i
Prepaid expenses & other curre	0.3	0.2	(0.0)	(0.0)	0.4	0.1	(0.2)	0.0	0.1	0.2	0.0	(0.2)	0.3	0.0	0.2	0.0	0.0	0.0	(0.0)	
Income tax	0.0	0.2	(0.1)	(0.1)	0.0	0.1	(0.2)	0.1	0.1	0.0	0.0	(0.2)	0.0	0.0	0.0	0.0	0.0	0.0	(0.1)	\ \
Other assets					0.0					0.0			0.0	0.9	0.0	0.0	0.0	0.0	0.0	
Accounts payable	(0.2)	0.1	0.2	(0.0)	0.0	0.1	0.2	0.1	(1.3)	(0.8)	0.3	0.1	0.0	(1.2)	(0.7)	0.0	0.0	0.0	0.8	
Accrued expenses	(0.2)	0.1	0.2	(0.0)	0.0	0.1	0.2	0.1	(1.5)	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Other liabilities	(0.0)	(0.0)	(0.0)	(0.0)	(0.1)	(0.0)	(0.0)	(0.0)	(0.0)	(0.2)	(0.0)	(0.0)	0.0	0.0	(0.1)	0.0	0.0	0.0	0.0	0
Net cash (used in) provided by	(3.1)	(3.3)	(3.2)	(3.1)		(2.5)	(2.3)	(2.6)	(2.2)	(9.5)	(2.1)	(2.1)	(2.1)	(2.6)	(9.0)	(3.1)	(3.1)	(3.1)		(11
Cash flow from investing activit						(
Purchases of property and equip	(0.1)	(0.1)	(0.0)	(0.0)	(0.2)	(0.0)			0.0	(0.0)	(0.0)	0.0	(0.0)	(0.0)	(0.1)	(0.0)	(0.0)	(0.1)	(0.0)	
Purchases of short-term investm	ents				0.0					0.0					0.0					
Acquisitions					0.0					0.0					0.0					
Other					<u>0.0</u>					<u>0.0</u>	<u>0.0</u>				<u>0.0</u>					<u>(</u>
Net cash used in investing activ	(0.1)	(0.1)	(0.0)	(0.0)	(0.2)	(0.0)	0.0	0.0	0.0	(0.0)	(0.0)	0.0	(0.0)	(0.0)	(0.1)	(0.0)	(0.0)	(0.1)	(0.0)	(0
Cash flow from financing activit	ies																			
Issuance of debt					0.0					0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Repayment of debt					0.0					0.0	(0.0)				(0.0)					
Issuance of stock	0.9	7.5			8.4		4.7	1.1	0.7	6.5	0.4	0.7	0.0	0.0	1.1	0.0	0.0	0.0	0.0	
Proceeds from stock option exe	cises				0.0		0.0		1.0	1.0	0.1	6.6			6.7					
Other					0.0					0.0					0.0					
Dividends and distributions					0.0					0.0					0.0					
Cash provided by (used in) fina	0.9	7.5	0.0	0.0	8.4	0.0	4.7	1.1	1.7	7.5	0.5	7.3	0.0	0.0	7.8	0.0	0.0	0.0	0.0	
Effect of exchange rate on cash					0.0					0.0					0.0					
Net increase (decrease) in cash	(2.3)	4.2	(3.3)	(3.1)	(4.6)	(2.5)	2.5	(1.5)	(0.5)	(2.1)	(1.7)	5.3	(2.1)	(2.7)	(1.2)	(3.1)	(3.1)	(3.2)	(2.6)	(1
Beginning cash and equivalents	9.5	4.2 7.1	(3.3)	(3.1) 8.0	9.5	4.9	2.5	4.8	3.3	4.9	2.8	5.3 1.1	6.4	4.3	2.8	1.6	(1.5)	(3.2)		
Ending cash and equivalents	9.5 7.1	11.3	8.0	8.0 4.9	9.5 4.9	4.9 2.4	2.4 4.8	4.8	3.3 2.8	4.9 2.8	2.8	6.4	6.4 4.3	4.3	2.8	(1.5)	(1.5)	(4.7)		(1


Source: Company reports and Ascendiant Capital Markets estimates



ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendiant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

ENDRA Life Sciences Inc.



*Reflects a 1:50 reverse stock split in August 2024

	Report Date		Price
Report	Date	Rating	Target
1	4/10/2019	Buy	4,500.00
2	5/15/2019	Buy	4,250.00
3	8/12/2019	Buy	3,250.00
4	11/18/2019	Buy	2,750.00
5	1/28/2020	Buy	3,000.00
6	3/29/2020	Buy	2,500.00
7	5/19/2020	Buy	2,750.00
8	8/18/2020	Buy	3,250.00
9	11/21/2020	Buy	3,500.00
10	4/4/2021	Buy	5,500.00
11	5/31/2021	Buy	6,000.00
12	8/23/2021	Buy	6,500.00
13	11/17/2021	Buy	6,250.00
14	4/12/2022	Buy	5,500.00
15	6/5/2022	Buy	5,000.00
16	9/7/2022	Buy	4,500.00
17	11/21/2022	Buy	4,250.00
18	3/28/2023	Buy	1,500.00
19	5/30/2023	Buy	1,000.00
20	8/25/2023	Buy	850.00
21	11/20/2023	Buy	550.00
22	4/30/2024	Buy	500.00
23	6/6/2024	Buy	400.00

• Ascendiant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendiant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street



Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendiant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendiant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendiant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product/device candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech/medtech stocks, and changes in consumer or government priorities for healthcare.

Ascendiant Capital Markets, LLC Rating System

- **BUY:** We expect the stock to provide a total return of 15% or more within a 12-month period.
- **HOLD:** We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.
- SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendiant Capital Markets, LLC Distribution of Investment Ratings (as of July 12, 2024)

			Investment Banking Services Past 12 months						
Rating	Count	Percent	Count	Percent					
Buy	58	98%	21	36%					
Hold	0	0%	0	0%					
Sell	1	2%	0	0%					
Total	59	100%	21	36%					



Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendiant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendiant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendiant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendiant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendiant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendiant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendiant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendiant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendiant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.